- Global Pharma News & Resources

Organoids Market is projected to reach US$ 3,420.40 million by 2027 and to grow at a CAGR of 22.1%

The organoids market was valued at US$ 689.47 million in 2019 and it is projected to reach US$ 3,420.40 million by 2027; it is expected to grow at a CAGR of 22.1% from 2020 to 2027.

Organoids are tiny, self-organized three-dimensional tissue cultures that are derived from stem cells. Such cultures can be crafted to replicate much of the complexity of an organ, or to express selected aspects of it like producing only certain types of cells. Organoids grow from stem cells—cells that can divide indefinitely and produce different types of cells as part of their progeny. Organoids can range in size from less than the width of a hair to five millimeters.  

Request for sample @

Company Profiles

  • STEMCELL Technologies, Inc.
  • Cellesce Ltd.
  • Hubrecht Organoid Technology
  • Definigen
  • 3Dnamics, Inc.
  • Organoid Therapeutics
  • PeproTech, Inc.
  • Thermo Fisher Scientific
  • Corning Incorporated (Life Sciences)
  • Merck KGgA

Based on type, the global organoids market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. In 2019, the intestine segment held the largest market share. This segment is also expected to dominate the market in 2027 as various experimental techniques have also been developed in parallel with, and applied to, intestinal organoid cultures with a scientifically synergistic effect. Moreover, the kidney segment is anticipated to grow at the fastest rate during the forecast period.

Organoids are microscopic and self-organizing 3D structures, which are grown from stem cells in vitro. They review various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to the development of several novel human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing any combination of cancer gene alterations to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, becomes a model for the cancer microenvironment enabling immune-oncology applications. Also, recent studies have proved that organoids have a place in personalized medicine approaches.

Personalized medicine is a growing area of treatment that relies on specific drug delivery and dosing. As per a study published by Personalized Medicine Coalition (PMC), in 2005, personalized medicines accounted for only 5% of the new FDA approved molecular entities; whereas, they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years.

Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical settings. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcome.

Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.

Purchase Full Copy of This Report @

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876


Organoids Market  is projected to reach US$ 3,420.40 million by 2027 and to grow at a CAGR of 22.1%

Editor Details

Related Links

Last Updated: 09-Mar-2021